Dual-Payload ADC
| Program | Indication | Discovery | PCC | IND-enabling | Ph 1 | Ph 2 | Pivotal trial | |
|---|---|---|---|---|---|---|---|---|
| CAN016 | T-DXd resistant | US&China | FPI June 2026 | |||||
| CAN017 | CLDN18.2/PD-L1 | |||||||
| CAN018 | PD-L1 | |||||||
| CAN019 | CD70 | |||||||
| CAN020 | TROP2 | |||||||
| Target 5 | Solid tumor | |||||||
SMDC
| Program | Indication | Discovery | PCC | IND-enabling | Ph 1 | Ph 2 | Pivotal trial | |
|---|---|---|---|---|---|---|---|---|
| CAN1012(IFN-a biased TLR7 agonist) | Solid tumor | US&China | ||||||
| H&N Cancer Breast Cancer |
US | Neo-adjuvant trials | ||||||
| CAN1012 PD-1 Combo | Liposarcoma | ODD granted by FDA | ||||||
| Melanoma | ||||||||
| CAN2109(Long-acting ICD inducer) | Solid tumors | US&China | ||||||